Chong Kun Dang acquires U.S. process patent of CKD-11101, anemia therapy biosimilar
Chong Kun Dang(CEO Young-Joo Kim) announced on the 27th that the company acquired a process patent of ‘CKD-11101,’ a second-generation biosimilar for the treatment of anemia, in the U.S.
The process patent, a patent for the new process method of darbepoetin alfa, the main substance of CKD-11101,...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
